<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<html>
 <body>
  <pubmedarticleset>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32303915
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1179-1942
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Drug safety
       </title>
       <isoabbreviation>
        Drug Saf
       </isoabbreviation>
      </journal>
      <articletitle>
       Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s40264-020-00935-2
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Trifirò
        </lastname>
        <forename>
         Gianluca
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy. trifirog@unime.it.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Crisafulli
        </lastname>
        <forename>
         Salvatore
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Andò
        </lastname>
        <forename>
         Giuseppe
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Racagni
        </lastname>
        <forename>
         Giorgio
        </forename>
        <initials>
         G
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Drago
        </lastname>
        <forename>
         Filippo
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biomedical and Biotechnological Sciences, Clinical Pharmacology Unit of the University Hospital, University of Catania, Catania, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <collectivename>
         Italian Society of Pharmacology
        </collectivename>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       New Zealand
      </country>
      <medlineta>
       Drug Saf
      </medlineta>
      <nlmuniqueid>
       9002928
      </nlmuniqueid>
      <issnlinking>
       0114-5916
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <investigatorlist>
      <investigator validyn="Y">
       <lastname>
        Berrino
       </lastname>
       <forename>
        Liberato
       </forename>
       <initials>
        L
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Re
       </lastname>
       <forename>
        Marzia
       </forename>
       <initials>
        M
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Bernardini
       </lastname>
       <forename>
        Renato
       </forename>
       <initials>
        R
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Chiamulera
       </lastname>
       <forename>
        Cristiano
       </forename>
       <initials>
        C
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        D'Avolio
       </lastname>
       <forename>
        Antonio
       </forename>
       <initials>
        A
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Pani
       </lastname>
       <forename>
        Luca
       </forename>
       <initials>
        L
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Clementi
       </lastname>
       <forename>
        Emilio
       </forename>
       <initials>
        E
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Capuano
       </lastname>
       <forename>
        Annalisa
       </forename>
       <initials>
        A
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Scaglione
       </lastname>
       <forename>
        Francesco
       </forename>
       <initials>
        F
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Danesi
       </lastname>
       <forename>
        Romano
       </forename>
       <initials>
        R
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Cirino
       </lastname>
       <forename>
        Giuseppe
       </forename>
       <initials>
        G
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Mugelli
       </lastname>
       <forename>
        Alessandro
       </forename>
       <initials>
        A
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Bonanno
       </lastname>
       <forename>
        Giambattista
       </forename>
       <initials>
        G
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Brunello
       </lastname>
       <forename>
        Nicoletta
       </forename>
       <initials>
        N
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Luca
       </lastname>
       <forename>
        Annamaria
       </forename>
       <initials>
        A
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Hrelia
       </lastname>
       <forename>
        Patrizia
       </forename>
       <initials>
        P
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Pistis
       </lastname>
       <forename>
        Marco
       </forename>
       <initials>
        M
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Ghelardini
       </lastname>
       <forename>
        Carla
       </forename>
       <initials>
        C
       </initials>
      </investigator>
      <investigator validyn="Y">
       <lastname>
        Taglialatela
       </lastname>
       <forename>
        Maurizio
       </forename>
       <initials>
        M
       </initials>
      </investigator>
     </investigatorlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        19
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32303915
      </articleid>
      <articleid idtype="doi">
       10.1007/s40264-020-00935-2
      </articleid>
      <articleid idtype="pii">
       10.1007/s40264-020-00935-2
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32302265
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1524-4571
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          17
         </day>
        </pubdate>
       </journalissue>
       <title>
        Circulation research
       </title>
       <isoabbreviation>
        Circ. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1161/CIRCRESAHA.120.317134
      </elocationid>
      <abstract>
       <abstracttext>
        <b>
         Rationale:
        </b>
        Use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is a major concern for clinicians treating coronavirus disease 2019 (COVID-19) in patients with hypertension.
        <b>
         Objective:
        </b>
        To determine the association between in-hospital use of ACEI/ARB and all-cause mortality in COVID-19 patients with hypertension.
        <b>
         Methods and Results:
        </b>
        This retrospective, multi-center study included 1128 adult patients with hypertension diagnosed with COVID-19, including 188 taking ACEI/ARB (ACEI/ARB group; median age 64 [IQR 55-68] years; 53.2% men) and 940 without using ACEI/ARB (non-ACEI/ARB group; median age 64 [IQR 57-69]; 53.5% men), who were admitted to nine hospitals in Hubei Province, China from December 31, 2019 to February 20, 2020. Unadjusted mortality rate was lower in the ACEI/ARB group versus the non-ACEI/ARB group (3.7% vs. 9.8%; P = 0.01). In mixed-effect Cox model treating site as a random effect, after adjusting for age, gender, comorbidities, and in-hospital medications, the detected risk for all-cause mortality was lower in the ACEI/ARB group versus the non-ACEI/ARB group (adjusted HR, 0.42; 95% CI, 0.19-0.92; P =0.03). In a propensity score-matched analysis followed by adjusting imbalanced variables in mixed-effect Cox model, the results consistently demonstrated lower risk of COVID-19 mortality in patients who received ACEI/ARB versus those who did not receive ACEI/ARB (adjusted HR, 0.37; 95% CI, 0.15-0.89; P = 0.03). Further subgroup propensity score-matched analysis indicated that, compared to use of other antihypertensive drugs, ACEI/ARB was also associated with decreased mortality (adjusted HR, 0.30; 95%CI, 0.12-0.70; P = 0.01) in COVID-19 patients with hypertension.
        <b>
         Conclusions:
        </b>
        Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associated with lower risk of all-cause mortality compared with ACEI/ARB non-users. While study interpretation needs to consider the potential for residual confounders, it is unlikely that in-hospital use of ACEI/ARB was associated with an increased mortality risk.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Peng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         LiHua
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cai
        </lastname>
        <forename>
         Jingjing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, The Third Xiangya Hospital, Central South University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lei
        </lastname>
        <forename>
         Fang
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qin
        </lastname>
        <forename>
         Juan-Juan
        </forename>
        <initials>
         JJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xie
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Ye-Mao
        </forename>
        <initials>
         YM
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Yan-Ci
        </forename>
        <initials>
         YC
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Xuewei
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Lijin
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xia
        </lastname>
        <forename>
         Meng
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Ming-Ming
        </forename>
        <initials>
         MM
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Xu
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Xiao
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Eye Center, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Deliang
        </forename>
        <initials>
         D
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Peng
        </lastname>
        <forename>
         Yuanyuan
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Zhongnan Hospital, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ji
        </lastname>
        <forename>
         Yan-Xiao
        </forename>
        <initials>
         YX
        </initials>
        <affiliationinfo>
         <affiliation>
          Animal Biosafety Level-III Laboratory, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Model Animal, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         She
        </lastname>
        <forename>
         Zhi-Gang
        </forename>
        <initials>
         ZG
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Yibin
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Anesthesiology and Perioperative Medicine, University of California, Los Angeles, UNITED STATES.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xu
        </lastname>
        <forename>
         Qingbo
        </forename>
        <initials>
         Q
        </initials>
        <affiliationinfo>
         <affiliation>
          Centre for Clinic Pharmacology, William Harvey Research Institute, UNITED KINGDOM.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Tan
        </lastname>
        <forename>
         Renfu
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Wuhan Kanghuashuhai Technology Company, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Haitao
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatopancreatobiliary Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Lin
        </lastname>
        <forename>
         Jun
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Gastroenterology, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Luo
        </lastname>
        <forename>
         Pengcheng
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Urology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fu
        </lastname>
        <forename>
         Shouzhi
        </forename>
        <initials>
         S
        </initials>
        <affiliationinfo>
         <affiliation>
          Urology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cai
        </lastname>
        <forename>
         Hongbin
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan Ninth Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ye
        </lastname>
        <forename>
         Ping
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science of Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Bing
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Stomatology, Xiantao First People's Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mao
        </lastname>
        <forename>
         Weiming
        </forename>
        <initials>
         W
        </initials>
        <affiliationinfo>
         <affiliation>
          General Surgery, Huanggang Central Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Liming
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          General Surgery, Ezhou Central Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yan
        </lastname>
        <forename>
         Youqin
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Infections Department, Wuhan Seventh Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Mingyu
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Infections Department, Wuhan Ninth Hospital, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Manhua
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Xiao-Jing
        </forename>
        <initials>
         XJ
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Xinghuan
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Touyz
        </lastname>
        <forename>
         Rhian M
        </forename>
        <initials>
         RM
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Cardiovascular and Medical Sciences, University of Glasgow, UNITED KINGDOM.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xia
        </lastname>
        <forename>
         Jiahong
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Bing-Hong
        </forename>
        <initials>
         BH
        </initials>
        <affiliationinfo>
         <affiliation>
          Neonatology, Renmin Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Xiaodong
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          Tongren Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yuan
        </lastname>
        <forename>
         Yufeng
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rohit
        </lastname>
        <forename>
         Loomba
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          NAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California San Diego, UNITED STATES.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Liu
        </lastname>
        <forename>
         Peter P
        </forename>
        <initials>
         PP
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, University of Ottawa Heart Institute, CANADA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Li
        </lastname>
        <forename>
         Hongliang
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiology, Wuhan University, CHINA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        17
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Circ Res
      </medlineta>
      <nlmuniqueid>
       0047103
      </nlmuniqueid>
      <issnlinking>
       0009-7330
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACEI/ARB
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Pneumonia
      </keyword>
      <keyword majortopicyn="N">
       SARS-COV-2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32302265
      </articleid>
      <articleid idtype="doi">
       10.1161/CIRCRESAHA.120.317134
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32301766
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1533-4023
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of cardiovascular pharmacology
       </title>
       <isoabbreviation>
        J. Cardiovasc. Pharmacol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1097/FJC.0000000000000840
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Buckley
        </lastname>
        <forename>
         Leo F
        </forename>
        <initials>
         LF
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Brigham and Women's Hospital.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cheng
        </lastname>
        <forename>
         Judy W M
        </forename>
        <initials>
         JWM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Services, Brigham and Women's Hospital.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy Practice, MCPHS University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Desai
        </lastname>
        <forename>
         Akshay
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Division, Brigham and Women's Hospital.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Cardiovasc Pharmacol
      </medlineta>
      <nlmuniqueid>
       7902492
      </nlmuniqueid>
      <issnlinking>
       0160-2446
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        18
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32301766
      </articleid>
      <articleid idtype="doi">
       10.1097/FJC.0000000000000840
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32294179
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1945-7189
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Endocrine reviews
       </title>
       <isoabbreviation>
        Endocr. Rev.
       </isoabbreviation>
      </journal>
      <articletitle>
       Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       bnaa011
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1210/endrev/bnaa011
      </elocationid>
      <abstract>
       <abstracttext>
        Individuals with diabetes are at increased risk for bacterial, mycotic, parasitic and viral infections. The severe acute respiratory syndrome (SARS)-CoV2 (also referred to as COVID-19) coronavirus pandemic highlights the importance of understanding shared disease pathophysiology potentially informing therapeutic choices in individuals with Type 2 diabetes (T2D). Two coronavirus receptor proteins, Angiotensin Converting Enzyme 2 (ACE2) and Dipeptidyl Peptidase-4 (DPP4) are also established transducers of metabolic signals and pathways regulating inflammation, renal and cardiovascular physiology, and glucose homeostasis. Moreover, glucose-lowering agents such as the DPP4 inhibitors, widely used in subjects with T2D, are known to modify the biological activities of multiple immunomodulatory substrates. Here we review the basic and clinical science spanning the intersections of diabetes, coronavirus infections, ACE2, and DPP4 biology, highlighting clinical relevance and evolving areas of uncertainty underlying the pathophysiology and treatment of T2D in the context of coronavirus infection.
       </abstracttext>
       <copyrightinformation>
        © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Drucker
        </lastname>
        <forename>
         Daniel J
        </forename>
        <initials>
         DJ
        </initials>
        <affiliationinfo>
         <affiliation>
          From the Lunenfeld-Tanenbaum Research Institute, Department of Medicine, Mt. Sinai Hospital, University of Toronto, Toronto Ontario, Canada.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Endocr Rev
      </medlineta>
      <nlmuniqueid>
       8006258
      </nlmuniqueid>
      <issnlinking>
       0163-769X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Angiotensin Converting Enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Dipeptidyl Peptidase-4
      </keyword>
      <keyword majortopicyn="N">
       Obesity
      </keyword>
      <keyword majortopicyn="N">
       Receptor
      </keyword>
      <keyword majortopicyn="N">
       Virus
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32294179
      </articleid>
      <articleid idtype="pii">
       5820492
      </articleid>
      <articleid idtype="doi">
       10.1210/endrev/bnaa011
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32293003
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       17
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1755-3245
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cardiovascular research
       </title>
       <isoabbreviation>
        Cardiovasc. Res.
       </isoabbreviation>
      </journal>
      <articletitle>
       Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.
      </articletitle>
      <elocationid eidtype="pii" validyn="Y">
       cvaa097
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1093/cvr/cvaa097
      </elocationid>
      <abstract>
       <abstracttext>
        Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.
       </abstracttext>
       <copyrightinformation>
        Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kreutz
        </lastname>
        <forename>
         Reinhold
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Algharably
        </lastname>
        <forename>
         Engi Abd El-Hady
        </forename>
        <initials>
         EAE
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Azizi
        </lastname>
        <forename>
         Michel
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Université Paris-Descartes; AP-HP, Hôpital Européen Georges-Pompidou, Hypertension Department and DMU CARTE; INSERM, CIC1418, Paris, France.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Dobrowolski
        </lastname>
        <forename>
         Piotr
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guzik
        </lastname>
        <forename>
         Tomasz
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Cardiovascular &amp; Medical Sciences BHF Glasgow Cardiovascular Research Centre; Glasgow, UK and Jagiellonian University, Collegium Medicum, Krakow, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Januszewicz
        </lastname>
        <forename>
         Andrzej
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Persu
        </lastname>
        <forename>
         Alexandre
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Cardiology, Cliniques Universitaires Saint-Luc and Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Prejbisz
        </lastname>
        <forename>
         Aleksander
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Riemer
        </lastname>
        <forename>
         Thomas Günther
        </forename>
        <initials>
         TG
        </initials>
        <affiliationinfo>
         <affiliation>
          Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institut für Klinische Pharmakologie und Toxikologie, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Ji-Guang
        </forename>
        <initials>
         JG
        </initials>
        <affiliationinfo>
         <affiliation>
          The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Burnier
        </lastname>
        <forename>
         Michel
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Service of Nephrology and Hypertension, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Cardiovasc Res
      </medlineta>
      <nlmuniqueid>
       0077427
      </nlmuniqueid>
      <issnlinking>
       0008-6363
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       Angiotensin
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       Cardiovascular
      </keyword>
      <keyword majortopicyn="Y">
       Hypertension
      </keyword>
      <keyword majortopicyn="Y">
       Lung
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        01
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32293003
      </articleid>
      <articleid idtype="pii">
       5819836
      </articleid>
      <articleid idtype="doi">
       10.1093/cvr/cvaa097
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="In-Process">
     <pmid version="1">
      32291526
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1534-3170
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         22
        </volume>
        <issue>
         5
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Current cardiology reports
       </title>
       <isoabbreviation>
        Curr Cardiol Rep
       </isoabbreviation>
      </journal>
      <articletitle>
       Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
      </articletitle>
      <pagination>
       <medlinepgn>
        31
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s11886-020-01291-4
      </elocationid>
      <abstract>
       <abstracttext label="PURPOSE OF REVIEW">
        Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the aggressive coronavirus disease (COVID-19) pandemic. Recently, investigators have stipulated that COVID-19 patients receiving angiotensin-converting-enzyme inhibitors (ACEI) may be subject to poorer outcomes. This editorial presents the available evidence to guide treatment practices during this pandemic.
       </abstracttext>
       <abstracttext label="RECENT FINDINGS">
        Recent studies from Wuhan cohorts provide valuable information about COVID-19. A cohort with 52 critically ill patients revealed cardiac injury in 12% of patients. Worse outcomes appear to be more prevalent in patients with hypertension and diabetes mellitus (DM), possibly due to overexpression of angiotensin-converting enzyme 2 (ACE2) receptor in airway alveolar epithelial cells. Investigators suspect that SARS-CoV-2 uses the ACE2 receptor to enter the lungs in a mechanism similar to SARS-CoV. Several hypotheses have been proposed to date regarding the net effect of ACEI/ARB on COVID-19 infections. Positive effects include ACE2 receptor blockade, disabling viral entry into the heart and lungs, and an overall decrease in inflammation secondary to ACEI/ARB. Negative effects include a possible retrograde feedback mechanism, by which ACE2 receptors are upregulated. Even though physiological models of SARS-CoV infection show a theoretical benefit of ACEI/ARB, these findings cannot be extrapolated to SARS-CoV-2 causing COVID-19. Major cardiology scientific associations, including ACC, HFSA, AHA, and ESC Hypertension Council, have rejected these correlation hypotheses. After an extensive literature review, we conclude that there is no significant evidence to support an association for now, but given the rapid evolvement of this pandemic, findings may change.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rico-Mesa
        </lastname>
        <forename>
         Juan Simon
        </forename>
        <initials>
         JS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         White
        </lastname>
        <forename>
         Averi
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Anderson
        </lastname>
        <forename>
         Allen S
        </forename>
        <initials>
         AS
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, Division of Cardiovascular Diseases, University of Texas Health San Antonio, 7703 Floyd Curl Drive, MC 7872, San Antonio, TX, 78229, USA. Andersona4@uthscsa.edu.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Curr Cardiol Rep
      </medlineta>
      <nlmuniqueid>
       100888969
      </nlmuniqueid>
      <issnlinking>
       1523-3782
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2 receptor
      </keyword>
      <keyword majortopicyn="Y">
       ACEI
      </keyword>
      <keyword majortopicyn="Y">
       ARB
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       SARS-COV 2
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32291526
      </articleid>
      <articleid idtype="doi">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pii">
       10.1007/s11886-020-01291-4
      </articleid>
      <articleid idtype="pmc">
       PMC7154066
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Ther. 2010 Oct;128(1):119-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20599443
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Compr Physiol. 2014 Jul;4(3):1201-28
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24944035
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Res. 2017 Nov;125(Pt A):21-38
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28619367
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Allergy. 2020 Feb 19;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32077115
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 May;92(5):491-494
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32056249
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 02;48(0):E004
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32120458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Saudi Med. 2016 Jan-Feb;36(1):78-80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26922692
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trop Med Int Health. 2020 Mar;25(3):278-280
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32052514
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2005 May 24;111(20):2605-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15897343
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2020 Feb 28;368:m810
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32111649
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Feb 24;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105632
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Conn Med. 1965 Oct;29(10):710-1
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         4284109
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):219-222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32164092
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32290680
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2047-4881
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          15
         </day>
        </pubdate>
       </journalissue>
       <title>
        European journal of preventive cardiology
       </title>
       <isoabbreviation>
        Eur J Prev Cardiol
       </isoabbreviation>
      </journal>
      <articletitle>
       Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.
      </articletitle>
      <pagination>
       <medlinepgn>
        2047487320918421
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1177/2047487320918421
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sarzani
        </lastname>
        <forename>
         Riccardo
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Giulietti
        </lastname>
        <forename>
         Federico
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Pentima
        </lastname>
        <forename>
         Chiara Di
        </forename>
        <initials>
         CD
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Giordano
        </lastname>
        <forename>
         Piero
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Spannella
        </lastname>
        <forename>
         Francesco
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        15
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Eur J Prev Cardiol
      </medlineta>
      <nlmuniqueid>
       101564430
      </nlmuniqueid>
      <issnlinking>
       2047-4873
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32290680
      </articleid>
      <articleid idtype="doi">
       10.1177/2047487320918421
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32289115
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       16
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        2589-5559
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         2
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Jun
         </month>
        </pubdate>
       </journalissue>
       <title>
        JHEP reports : innovation in hepatology
       </title>
       <isoabbreviation>
        JHEP Rep
       </isoabbreviation>
      </journal>
      <articletitle>
       Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper.
      </articletitle>
      <pagination>
       <medlinepgn>
        100113
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.jhepr.2020.100113
      </elocationid>
      <abstract>
       <abstracttext>
        The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.
       </abstracttext>
       <copyrightinformation>
        © 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Boettler
        </lastname>
        <forename>
         Tobias
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Newsome
        </lastname>
        <forename>
         Philip N
        </forename>
        <initials>
         PN
        </initials>
        <affiliationinfo>
         <affiliation>
          National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Centre for Liver &amp; Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mondelli
        </lastname>
        <forename>
         Mario U
        </forename>
        <initials>
         MU
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Maticic
        </lastname>
        <forename>
         Mojca
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Faculty of Medicine, University of Ljubljana, Slovenia.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cordero
        </lastname>
        <forename>
         Elisa
        </forename>
        <initials>
         E
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, University of Seville, Clinical Unit of Infectious Diseases University Hospital Virgen del Rocio, Institute of Biomedicine, Sevilla, CSIC, Spain.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cornberg
        </lastname>
        <forename>
         Markus
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Centre for Individualised Infection Medicine (CIIM), Hannover, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Berg
        </lastname>
        <forename>
         Thomas
        </forename>
        <initials>
         T
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Hepatology, Clinic and Polyclinic for Gastroenterology, Hepatology, Infectious Diseases, and Pneumology, University Hospital Leipzig, Leipzig, Germany.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        02
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Netherlands
      </country>
      <medlineta>
       JHEP Rep
      </medlineta>
      <nlmuniqueid>
       101761237
      </nlmuniqueid>
      <issnlinking>
       2589-5559
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE-I, angiotensin-converting enzyme inhibitor
      </keyword>
      <keyword majortopicyn="N">
       ACE2, angiotensin-converting enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       ACLF, acute-on-chronic liver failure
      </keyword>
      <keyword majortopicyn="N">
       ALT, alanine aminotransferase
      </keyword>
      <keyword majortopicyn="N">
       AST, aspartate aminotransferase
      </keyword>
      <keyword majortopicyn="N">
       COVID-19, coronavirus disease 2019
      </keyword>
      <keyword majortopicyn="N">
       EGD, esophagogastroduodenoscopy
      </keyword>
      <keyword majortopicyn="N">
       ERC, endoscopic retrograde cholangiography
      </keyword>
      <keyword majortopicyn="N">
       HCC, hepatocellular carcinoma
      </keyword>
      <keyword majortopicyn="N">
       MELD, model for end-stage liver disease
      </keyword>
      <keyword majortopicyn="N">
       NAFLD, non-alcoholic fatty liver disease
      </keyword>
      <keyword majortopicyn="N">
       NASH, non-alcoholic steatohepatitis
      </keyword>
      <keyword majortopicyn="N">
       NUC, nucleoside analogue
      </keyword>
      <keyword majortopicyn="N">
       PIs, protease inhibitors
      </keyword>
      <keyword majortopicyn="N">
       RdRp, RNA-dependent RNA polymerase
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
      </keyword>
      <keyword majortopicyn="N">
       ULN, upper limit of normal
      </keyword>
     </keywordlist>
     <coistatement>
      Dr Berg reports grants, personal fees and non-financial support from Gilead. Dr Boettler reports consultancy fees from Gilead. Dr Cornberg reports personal fees from Gilead. All other authors report no conflicts of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        25
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32289115
      </articleid>
      <articleid idtype="doi">
       10.1016/j.jhepr.2020.100113
      </articleid>
      <articleid idtype="pii">
       S2589-5559(20)30047-1
      </articleid>
      <articleid idtype="pii">
       100113
      </articleid>
      <articleid idtype="pmc">
       PMC7128473
      </articleid>
     </articleidlist>
     <?pmcsd ?>
     <referencelist>
      <reference>
       <citation>
        Mayo Clin Proc. 2010 May;85(5):451-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20357277
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 6;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32155444
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Antimicrob Agents. 2020 Mar 20;:105949
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205204
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hepatol. 2019 Apr;70(4):797-799
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30635243
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drugs. 2017 Apr;77(6):697-704
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28290136
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2020 Mar;19(3):149-150
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32127666
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Oral Sci. 2020 Feb 24;12(1):8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32094336
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Feb 24;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105632
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Antimicrob Agents Chemother. 2013 Apr;57(4):1743-55
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23357765
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arthritis Rheumatol. 2017 Sep;69(9):1751-1761
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28597609
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32145190
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Gastroenterol Hepatol. 2020 Apr;5(4):335-337
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32087098
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Infect Dis. 2020 Mar 12;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32173574
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):420-422
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32085846
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Trials. 2019 Aug 14;20(1):501
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31412955
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Ther. 2020;14(1):58-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147628
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125362
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biosci Trends. 2020 Mar 16;14(1):72-73
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32074550
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        HIV Clin Trials. 2011 Sep-Oct;12(5):235-43
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22180521
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):e30-e31
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32032529
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Life Sci. 2020 May 1;248:117477
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32119961
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 5;382(10):929-936
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32004427
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Gastroenterology. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32142785
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32054787
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 27;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32219428
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2020 Mar 19;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32201338
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hepatol. 2016 Nov;65(5):899-905
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27388923
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMC Infect Dis. 2020 Jan 28;20(1):80
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31992207
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hepatol. 2014 Dec;61(6):1385-96
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25135860
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2016 Mar 17;531(7594):381-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26934220
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Transplant. 2020 Mar 17;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32181990
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Commun. 2020 Jan 10;11(1):222
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31924756
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Liver Int. 2020 Mar 14;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32170806
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32142651
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Int J Rheum Dis. 2017 Jul;20(7):859-869
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28160426
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 20;43(0):E019
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32075365
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1033-1034
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32192578
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Biotechnol. 2020 Apr;38(4):379-381
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32205870
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28596841
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 11;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32160451
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32286790
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1936-086X
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          16
         </day>
        </pubdate>
       </journalissue>
       <title>
        ACS nano
       </title>
       <isoabbreviation>
        ACS Nano
       </isoabbreviation>
      </journal>
      <articletitle>
       Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1021/acsnano.0c02857
      </elocationid>
      <abstract>
       <abstracttext>
        Peptide inhibitors against the SARS-CoV-2 coronavirus, currently causing a worldwide pandemic, are designed and simulated. The inhibitors are mostly formed by two sequential self-supporting α-helices (bundle) extracted from the protease domain (PD) of angiotensin-converting enzyme 2 (ACE2), which bind to the SARS-CoV-2 receptor binding domains. Molecular dynamics simulations revealed that the α-helical peptides maintain their secondary structure and provide a highly specific and stable binding (blocking) to SARS-CoV-2. To provide a multivalent binding to the SARS-CoV-2 receptors, many such peptides could be attached to the surfaces of nanoparticle carriers. The proposed peptide inhibitors could provide simple and efficient therapeutics against the COVID-19 disease.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Han
        </lastname>
        <forename>
         Yanxiao
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Král
        </lastname>
        <forename>
         Petr
        </forename>
        <initials>
         P
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0003-2992-9027
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Chemistry, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Physics, Biopharmaceutical Sciences, and Chemical Engineering, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        16
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       ACS Nano
      </medlineta>
      <nlmuniqueid>
       101313589
      </nlmuniqueid>
      <issnlinking>
       1936-0851
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       molecular dynamics simulations
      </keyword>
      <keyword majortopicyn="N">
       peptide inhibitors
      </keyword>
      <keyword majortopicyn="N">
       therapeutics
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32286790
      </articleid>
      <articleid idtype="doi">
       10.1021/acsnano.0c02857
      </articleid>
      <articleid idtype="pmc">
       PMC7163933
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Comput Biol Chem. 2007 Apr;31(2):134-7
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17368104
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Annu Rev Virol. 2016 Sep 29;3(1):237-261
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27578435
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Comput Chem. 2005 Dec;26(16):1781-802
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16222654
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Phys Chem B. 1998 Apr 30;102(18):3586-616
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24889800
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Drug Discov. 2008 Jan;7(1):21-39
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18097458
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2020 Mar 17;94(7):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31996437
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Mater. 2018 Feb;17(2):195-203
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29251725
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Microbiol. 2020 Apr;5(4):536-544
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32123347
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Adv. 2020 Jan 29;6(5):eaax9318
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32064341
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anal Biochem. 2005 Feb 15;337(2):262-70
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15691506
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2020 Mar 13;367(6483):1260-1263
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32075877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2020 Mar 27;367(6485):1444-1448
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32132184
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Opin Drug Deliv. 2018 Aug;15(8):729-736
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30025210
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Chem Soc Rev. 2018 Jun 5;47(11):3849-3860
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         29645040
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Virol. 2003 Aug;77(16):8801-11
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         12885899
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32286678
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1897-5593
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          14
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cardiology journal
       </title>
       <isoabbreviation>
        Cardiol J
       </isoabbreviation>
      </journal>
      <articletitle>
       Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.5603/CJ.a2020.0056
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Huang
        </lastname>
        <forename>
         Ziyin
        </forename>
        <initials>
         Z
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Soochow University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jiang
        </lastname>
        <forename>
         Yufeng
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Soochow University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Jingjing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Soochow University.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhou
        </lastname>
        <forename>
         Yafeng
        </forename>
        <initials>
         Y
        </initials>
        <affiliationinfo>
         <affiliation>
          The First Affiliated Hospital of Soochow University. zhouyafeng73@126.com.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        14
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Poland
      </country>
      <medlineta>
       Cardiol J
      </medlineta>
      <nlmuniqueid>
       101392712
      </nlmuniqueid>
      <issnlinking>
       1898-018X
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       angiotensin-converting enzyme inhibitors
      </keyword>
      <keyword majortopicyn="N">
       renin–angiotensin system
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        11
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32286678
      </articleid>
      <articleid idtype="pii">
       VM/OJS/J/68220
      </articleid>
      <articleid idtype="doi">
       10.5603/CJ.a2020.0056
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32282022
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-3598
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          13
         </day>
        </pubdate>
       </journalissue>
       <title>
        JAMA
       </title>
       <isoabbreviation>
        JAMA
       </isoabbreviation>
      </journal>
      <articletitle>
       Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1001/jama.2020.6019
      </elocationid>
      <abstract>
       <abstracttext label="Importance" nlmcategory="UNASSIGNED">
        The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
       </abstracttext>
       <abstracttext label="Observations" nlmcategory="UNASSIGNED">
        No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
       </abstracttext>
       <abstracttext label="Conclusions and Relevance" nlmcategory="UNASSIGNED">
        The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Sanders
        </lastname>
        <forename>
         James M
        </forename>
        <initials>
         JM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Monogue
        </lastname>
        <forename>
         Marguerite L
        </forename>
        <initials>
         ML
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jodlowski
        </lastname>
        <forename>
         Tomasz Z
        </forename>
        <initials>
         TZ
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmacy Service, VA North Texas Health Care System, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cutrell
        </lastname>
        <forename>
         James B
        </forename>
        <initials>
         JB
        </initials>
        <affiliationinfo>
         <affiliation>
          Division of Infectious Diseases and Geographic Medicine, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        13
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       JAMA
      </medlineta>
      <nlmuniqueid>
       7501160
      </nlmuniqueid>
      <issnlinking>
       0098-7484
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      AIM
     </citationsubset>
     <citationsubset>
      IM
     </citationsubset>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32282022
      </articleid>
      <articleid idtype="pii">
       2764727
      </articleid>
      <articleid idtype="doi">
       10.1001/jama.2020.6019
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32281328
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        1001-5302
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         45
        </volume>
        <issue>
         6
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
        </pubdate>
       </journalissue>
       <title>
        Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
       </title>
       <isoabbreviation>
        Zhongguo Zhong Yao Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Study on screening potential traditional Chinese medicines against 2019-nCoV based on Mpro and PLP].
      </articletitle>
      <pagination>
       <medlinepgn>
        1219-1224
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.19540/j.cnki.cjcmm.20200216.401
      </elocationid>
      <abstract>
       <abstracttext>
        With the rapid outbreak of COVID-19, traditional Chinese medicine(TCM) has been playing an active role against the epidemic. However, the screening of TCM is limited by the development cycle and laboratory conditions, which greatly limits the screening speed. This study established optimization docking models and virtual screening to discovery potential active herbs for the prevention and treatment of the novel coronavirus based on molecular docking technology. The crystal structures of 3 CL protease(Mpro) and papain-like protease(PLP) were obtained from PDB database and homologous modeling respectively, and were used to conduct virtual screening of TCMD 2009 database by CDOCKER program. The ingredients scored in the top 100 were selected respectively, and the candidate herbs were ranked by the numbers of hit molecules. Based on Mpro inhibitors screening, 12 322 potential active components were obtained, and the representative active components included aster pentapeptide A, ligustrazine, salvianolic acid B, etc., and Zingiberis Rhizoma Recens, Asteris Radix et Rhizoma, Notoginseng Radix et Rhizoma, Chuanxiong Rhizoma, Salviae Miltiorrhizae Radix et Rhizoma, Zingiberis Rhizoma, Dianthi Herba, Rhei Radix et Rhizoma, Cistanches Herba were obtained. While 11 294 potential active ingredients were obtained by PLP inhibitor screening, representative active ingredients included gingerketophenol, ginkgol alcohol, ferulic acid, etc., and Codonopsis Radix, Notopterygii Rhizoma et Radix, Zingiberis Rhizoma Recens, Ginkgo Semen, Chuanxiong Rhizoma, Trichosanthis Fructus, Paeoniae Radix Alba, Psoraleae Fructus, Sophorae Flavescentis Radix, Notoginseng Radix et Rhizoma, Angelicae Sinensis Radix were chosen. By combining the diagnosis and treatment scheme of Hunan province's and angiotensin converting enzyme 2(ACE2) inhibitors screening from literature, present study also discussed the rational application of candidate herbs to this epidemic situation. Trichosanthis Fructus obtained by PLP inhibitors screening and Fritillaria verticillata obtained by ACE2 inhibitors screening were parts of the Sangbei Zhisou Powder and Xiaoxianxiong Decoction, which might be applicable to the syndromes of cough and dyspnea. Rhei Radix et Rhizoma screened by Mpro and Trichosanthis Fructus screened by PLP were contained in Maxing Shigan Decoction and Xuanbai Chengqi Decoction, and could be applied to the syndromes of epidemic virus blocking lung. Mori Folium, Lonicerae Japonicae Flos and Forsythiae Fructus obtained by ACE2 inhibitors screening were included in the Sangju Decoction and Yinqiaosan, which might be applicable to the syndromes of warm pathogen attacking lung and cough and dyspnea. The results of this study are intended to provide a reference for the further development of traditional Chinese medicine to deal with the new epidemic.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Ma
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          State Administration of Traditional Chinese Medicine, Research Center of Traditional Chinese Medicine-Information Engineering, Key Technology of Traditional Chinese Medicine Pharmacy and New Drug Development Engineering Research Center of Ministry of Education, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Huo
        </lastname>
        <forename>
         Xiao-Qian
        </forename>
        <initials>
         XQ
        </initials>
        <affiliationinfo>
         <affiliation>
          State Administration of Traditional Chinese Medicine, Research Center of Traditional Chinese Medicine-Information Engineering, Key Technology of Traditional Chinese Medicine Pharmacy and New Drug Development Engineering Research Center of Ministry of Education, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chen
        </lastname>
        <forename>
         Xi
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          State Administration of Traditional Chinese Medicine, Research Center of Traditional Chinese Medicine-Information Engineering, Key Technology of Traditional Chinese Medicine Pharmacy and New Drug Development Engineering Research Center of Ministry of Education, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhu
        </lastname>
        <forename>
         Wei-Xing
        </forename>
        <initials>
         WX
        </initials>
        <affiliationinfo>
         <affiliation>
          Qingyuan Hospital of Traditional Chinese Medicine Qingyuan 511500, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Yao
        </lastname>
        <forename>
         Mei-Cun
        </forename>
        <initials>
         MC
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Pharmaceutical Sciences, Sun Yat-sen University Shenzhen 510275, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qiao
        </lastname>
        <forename>
         Yan-Jiang
        </forename>
        <initials>
         YJ
        </initials>
        <affiliationinfo>
         <affiliation>
          State Administration of Traditional Chinese Medicine, Research Center of Traditional Chinese Medicine-Information Engineering, Key Technology of Traditional Chinese Medicine Pharmacy and New Drug Development Engineering Research Center of Ministry of Education, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Yan-Ling
        </forename>
        <initials>
         YL
        </initials>
        <affiliationinfo>
         <affiliation>
          State Administration of Traditional Chinese Medicine, Research Center of Traditional Chinese Medicine-Information Engineering, Key Technology of Traditional Chinese Medicine Pharmacy and New Drug Development Engineering Research Center of Ministry of Education, School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhongguo Zhong Yao Za Zhi
      </medlineta>
      <nlmuniqueid>
       8913656
      </nlmuniqueid>
      <issnlinking>
       1001-5302
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004365">
        Drugs, Chinese Herbal
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004353">
        Drug Evaluation, Preclinical
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004365">
        Drugs, Chinese Herbal
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D008516">
        Medicine, Chinese Traditional
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D062105">
        Molecular Docking Simulation
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       3CL hydrolase
      </keyword>
      <keyword majortopicyn="N">
       angiotensin converting enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       molecular docking
      </keyword>
      <keyword majortopicyn="N">
       papain-like protease
      </keyword>
      <keyword majortopicyn="N">
       traditional Chinese medicine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281328
      </articleid>
      <articleid idtype="doi">
       10.19540/j.cnki.cjcmm.20200216.401
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation indexingmethod="Curated" owner="NLM" status="MEDLINE">
     <pmid version="1">
      32281327
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       14
      </day>
     </daterevised>
     <article pubmodel="Print">
      <journal>
       <issn issntype="Print">
        1001-5302
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         45
        </volume>
        <issue>
         6
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Mar
         </month>
        </pubdate>
       </journalissue>
       <title>
        Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
       </title>
       <isoabbreviation>
        Zhongguo Zhong Yao Za Zhi
       </isoabbreviation>
      </journal>
      <articletitle>
       [Rapid establishment of traditional Chinese medicine prevention and treatment of 2019-nCoV based on clinical experience and molecular docking].
      </articletitle>
      <pagination>
       <medlinepgn>
        1213-1218
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.19540/j.cnki.cjcmm.20200206.501
      </elocationid>
      <abstract>
       <abstracttext>
        The coronavirus disease 2019(COVID-19) is raging in China and more than 20 other countries and regions since the middle of December 2019. Currently, there is no specific drug or vaccine besides symptomatic supportive therapy. Taking full advantage of the clinical experience of traditional Chinese medicine(TCM) in preventing and controlling major epidemics such as SARS, it is an important mission for TCM to propose effective formula with immediate response and solid evidence by using modern biomedical knowledge and techniques(molecular docking assisted TCM formulation for short). In view of the high homology between the gene sequences of the novel coronavirus and SARS virus, and the similarities between the two in terms of pathogenic mechanism and clinical manifestations, our team established a rapid screening and optimization model for the prevention and treatment of the novel coronavirus based on clinical experience and molecular docking technology. Firstly, the clinical team and the research team pre-developed and screened TCM formula by using &amp;quot;back-to-back&amp;quot; manner. Then, the formula was optimized and determined by comparing and analyzing the results of the two groups. The results showed that the research team screened out 46 active ingredients from candidate TCMs that could act on the novel coronavirus S-protein-binding site of human ACE2 protein, which were mainly attributed to 7 herbs such as Lonicerae Japonicae Flos and Mori Folium. The result was largely consistent with the formula raised by the clinical group, verifying and supporting its rationality. This provides evidence for the scientific and potential efficacy of the TCM prescription from the perspective of treatment target analysis, and also suggests that the TCM prescription has the potential to directly inhibit viral infection in addition to improving clinical symptoms or syndromes. Based on this, our team optimized and formed a new anti-coronavirus TCM prescription &amp;quot;Keguan Yihao&amp;quot;, immediately providing the TCM prescription with certain clinical experience and objective evidence support for the prevention and treatment of new emergent infectious diseases in our hospital. The TCM prescription was combined with modern medicine symptomatic supportive treatment for clinical treatment, preliminary results showed better effect than symptomatic supportive therapy alone. This research has innovated the method mode in clinical practice and basic research integration of traditional Chinese medicine for the prevention and control of new emerging infectious diseases. It is of great significance to further improve the rapid response mechanism of TCM in face of major epidemics, and further improve the capability level of TCM to prevent and treat new emerging infectious diseases.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Niu
        </lastname>
        <forename>
         Ming
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Rui-Lin
        </forename>
        <initials>
         RL
        </initials>
        <affiliationinfo>
         <affiliation>
          Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Zhong-Xia
        </forename>
        <initials>
         ZX
        </initials>
        <affiliationinfo>
         <affiliation>
          Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Ping
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bai
        </lastname>
        <forename>
         Zhao-Fang
        </forename>
        <initials>
         ZF
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Jing
        </lastname>
        <forename>
         Jing
        </forename>
        <initials>
         J
        </initials>
        <affiliationinfo>
         <affiliation>
          Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Guo
        </lastname>
        <forename>
         Yu-Ming
        </forename>
        <initials>
         YM
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhao
        </lastname>
        <forename>
         Xu
        </forename>
        <initials>
         X
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhan
        </lastname>
        <forename>
         Xiao-Yan
        </forename>
        <initials>
         XY
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zhang
        </lastname>
        <forename>
         Zi-Teng
        </forename>
        <initials>
         ZT
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Song
        </lastname>
        <forename>
         Xue-Ai
        </forename>
        <initials>
         XA
        </initials>
        <affiliationinfo>
         <affiliation>
          Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qin
        </lastname>
        <forename>
         En-Qiang
        </forename>
        <initials>
         EQ
        </initials>
        <affiliationinfo>
         <affiliation>
          Infectious Disease Treatment and Investigation Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Wang
        </lastname>
        <forename>
         Jia-Bo
        </forename>
        <initials>
         JB
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Xiao
        </lastname>
        <forename>
         Xiao-He
        </forename>
        <initials>
         XH
        </initials>
        <affiliationinfo>
         <affiliation>
          China Military Institute of Chinese Medicine,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China Integrative Medical Center,Fifth Medical Center of Chinese PLA General Hospital Beijing 100039,China.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       chi
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
     </article>
     <medlinejournalinfo>
      <country>
       China
      </country>
      <medlineta>
       Zhongguo Zhong Yao Za Zhi
      </medlineta>
      <nlmuniqueid>
       8913656
      </nlmuniqueid>
      <issnlinking>
       1001-5302
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D004365">
        Drugs, Chinese Herbal
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D064370">
        Spike Glycoprotein, Coronavirus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="C000657845">
        spike glycoprotein, COVID-19 virus
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" type="Geographic" ui="D002681">
        China
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D004365">
        Drugs, Chinese Herbal
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000494">
        pharmacology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D008516">
        Medicine, Chinese Traditional
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D062105">
        Molecular Docking Simulation
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D064370">
        Spike Glycoprotein, Coronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000737">
        chemistry
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       2019-nCoV
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       clinical practice and basic research integration
      </keyword>
      <keyword majortopicyn="N">
       formula screening
      </keyword>
      <keyword majortopicyn="N">
       molecular docking
      </keyword>
      <keyword majortopicyn="N">
       traditional Chinese medicine
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        15
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      ppublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32281327
      </articleid>
      <articleid idtype="doi">
       10.19540/j.cnki.cjcmm.20200206.501
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32278764
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       18
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1872-8227
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         162
        </volume>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Diabetes research and clinical practice
       </title>
       <isoabbreviation>
        Diabetes Res. Clin. Pract.
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19 and diabetes: Knowledge in progress.
      </articletitle>
      <pagination>
       <medlinepgn>
        108142
       </medlinepgn>
      </pagination>
      <elocationid eidtype="pii" validyn="Y">
       S0168-8227(20)30392-2
      </elocationid>
      <elocationid eidtype="doi" validyn="Y">
       10.1016/j.diabres.2020.108142
      </elocationid>
      <abstract>
       <abstracttext label="AIMS" nlmcategory="OBJECTIVE">
        We aimed to briefly review the general characteristics of the novel coronavirus (SARS-CoV-2) and provide a better understanding of the coronavirus disease (COVID-19) in people with diabetes, and its management.
       </abstracttext>
       <abstracttext label="METHODS" nlmcategory="METHODS">
        We searched for articles in PubMed and Google Scholar databases till 02 April 2020, with the following keywords: "SARS-CoV-2", "COVID-19", "infection", "pathogenesis", "incubation period", "transmission", "clinical features", "diagnosis", "treatment", "diabetes", with interposition of the Boolean operator "AND".
       </abstracttext>
       <abstracttext label="RESULTS" nlmcategory="RESULTS">
        The clinical spectrum of COVID-19 is heterogeneous, ranging from mild flu-like symptoms to acute respiratory distress syndrome, multiple organ failure and death. Older age, diabetes and other comorbidities are reported as significant predictors of morbidity and mortality. Chronic inflammation, increased coagulation activity, immune response impairment, and potential direct pancreatic damage by SARS-CoV-2 might be among the underlying mechanisms of the association between diabetes and COVID-19. No conclusive evidence exists to support the discontinuation of angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers or thiazolidinediones because of COVID-19 in people with diabetes. Caution should be taken to potential hypoglycemic events with the use of chloroquine in these subjects. Patient tailored therapeutic strategies, rigorous glucose monitoring and careful consideration of drug interactions might reduce adverse outcomes.
       </abstracttext>
       <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
        Suggestions are made on the possible pathophysiological mechanisms of the relationship between diabetes and COVID-19, and its management. No definite conclusions can be made based on current limited evidence. Further research regarding this relationship and its clinical management is warranted.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hussain
        </lastname>
        <forename>
         Akhtar
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Faculty of Health Sciences, Nord University, Bodø 8049, Norway; Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil; International Diabetes Federation (IDF), 166 Chaussee de La Hulpe, B - 1170 Brussels, Belgium; Diabetes Asian Study Group (DASG), Ambwadi, Ahmedabad 380015, Gujarat, India; Centre for Global Health Research, Diabetic Association of Bangladesh, Dhaka 1000, Bangladesh. Electronic address: hussain.akhtar@nord.no.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Bhowmik
        </lastname>
        <forename>
         Bishwajit
        </forename>
        <initials>
         B
        </initials>
        <affiliationinfo>
         <affiliation>
          Centre for Global Health Research, Diabetic Association of Bangladesh, Dhaka 1000, Bangladesh; Institute of Health and Society, Department of Community Medicine and Global Health, University of Oslo (UiO), Oslo 0318, Norway.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         do Vale Moreira
        </lastname>
        <forename>
         Nayla Cristina
        </forename>
        <initials>
         NC
        </initials>
        <affiliationinfo>
         <affiliation>
          Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Brazil; Institute of Health and Society, Department of Community Medicine and Global Health, University of Oslo (UiO), Oslo 0318, Norway.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Ireland
      </country>
      <medlineta>
       Diabetes Res Clin Pract
      </medlineta>
      <nlmuniqueid>
       8508335
      </nlmuniqueid>
      <issnlinking>
       0168-8227
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Clinical management
      </keyword>
      <keyword majortopicyn="N">
       Diabetes
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
     </keywordlist>
     <coistatement>
      Declaration of Competing Interest None.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        13
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32278764
      </articleid>
      <articleid idtype="pii">
       S0168-8227(20)30392-2
      </articleid>
      <articleid idtype="doi">
       10.1016/j.diabres.2020.108142
      </articleid>
      <articleid idtype="pmc">
       PMC7144611
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32277367
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1434-9949
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Clinical rheumatology
       </title>
       <isoabbreviation>
        Clin. Rheumatol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s10067-020-05073-9
      </elocationid>
      <abstract>
       <abstracttext>
        The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern. Environmental factors such as air pollution and smoking and comorbid conditions (hypertension, diabetes mellitus and underlying cardio-respiratory illness) likely increase the severity of COVID-19. Rheumatic manifestations such as arthralgias and arthritis may be prevalent in about a seventh of individuals. COVID-19 can result in acute interstitial pneumonia, myocarditis, leucopenia (with lymphopenia) and thrombocytopenia, also seen in rheumatic diseases like lupus and Sjogren's syndrome. Severe disease in a subset of patients may be driven by cytokine storm, possibly due to secondary hemophagocytic lymphohistiocytosis (HLH), akin to that in systemic onset juvenile idiopathic arthritis or adult-onset Still's disease. In the absence of high-quality evidence in this emerging disease, understanding of pathogenesis may help postulate potential therapies. Angiotensin converting enzyme 2 (ACE2) appears important for viral entry into pneumocytes; dysbalance in ACE2 as caused by ACE inhibitors or ibuprofen may predispose to severe disease. Preliminary evidence suggests potential benefit with chloroquine or hydroxychloroquine. Antiviral drugs like lopinavir/ritonavir, favipiravir and remdesivir are also being explored. Cytokine storm and secondary HLH might require heightened immunosuppressive regimens. Current international society recommendations suggest that patients with rheumatic diseases on immunosuppressive therapy should not stop glucocorticoids during COVID-19 infection, although minimum possible doses may be used. Disease-modifying drugs should be continued; cessation may be considered during infection episodes as per standard practices. Development of a vaccine may be the only effective long-term protection against this disease.Key Points• Patients with coronavirus disease 19 (COVID-19) may have features mimicking rheumatic diseases, such as arthralgias, acute interstitial pneumonia, myocarditis, leucopenia, lymphopenia, thrombocytopenia and cytokine storm with features akin to secondary hemophagocytic lymphohistiocytosis.• Although preliminary results may be encouraging, high-quality clinical trials are needed to better understand the role of drugs commonly used in rheumatology like hydroxychloroquine and tocilizumab in COVID-19.• Until further evidence emerges, it may be cautiously recommended to continue glucocorticoids and other disease-modifying antirheumatic drugs (DMARDs) in patients receiving these therapies, with discontinuation of DMARDs during infections as per standard practice.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Misra
        </lastname>
        <forename>
         Durga Prasanna
        </forename>
        <initials>
         DP
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-5035-7396
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. durgapmisra@gmail.com.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Agarwal
        </lastname>
        <forename>
         Vikas
        </forename>
        <initials>
         V
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4508-1233
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Gasparyan
        </lastname>
        <forename>
         Armen Yuri
        </forename>
        <initials>
         AY
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0001-8749-6018
        </identifier>
        <affiliationinfo>
         <affiliation>
          Departments of Rheumatology and Research and Development, Dudley Group NHS Foundation Trust (Teaching Trust of the University of Birmingham, UK), Russells Hall Hospital, Dudley, West Midlands, UK.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Zimba
        </lastname>
        <forename>
         Olena
        </forename>
        <initials>
         O
        </initials>
        <identifier source="ORCID">
         https://orcid.org/0000-0002-4188-8486
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine #2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Clin Rheumatol
      </medlineta>
      <nlmuniqueid>
       8211469
      </nlmuniqueid>
      <issnlinking>
       0770-3198
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       Epidemiology
      </keyword>
      <keyword majortopicyn="N">
       Hydroxychloroquine
      </keyword>
      <keyword majortopicyn="N">
       Hypothesis
      </keyword>
      <keyword majortopicyn="N">
       Immunity
      </keyword>
      <keyword majortopicyn="N">
       Pathogenesis
      </keyword>
      <keyword majortopicyn="N">
       Vaccines
      </keyword>
      <keyword majortopicyn="N">
       Vitamin D
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        24
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        31
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="revised">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        29
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        12
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32277367
      </articleid>
      <articleid idtype="doi">
       10.1007/s10067-020-05073-9
      </articleid>
      <articleid idtype="pii">
       10.1007/s10067-020-05073-9
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32274964
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       10
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1538-0254
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          10
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of biomolecular structure &amp; dynamics
       </title>
       <isoabbreviation>
        J. Biomol. Struct. Dyn.
       </isoabbreviation>
      </journal>
      <articletitle>
       A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin.
      </articletitle>
      <pagination>
       <medlinepgn>
        1-13
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1080/07391102.2020.1754293
      </elocationid>
      <abstract>
       <abstracttext>
        The widespread antigenic changes lead to the emergence of a new type of coronavirus (CoV) called as severe acute respiratory syndrome (SARS)-CoV-2 that is immunologically different from the previous circulating species. Angiotensin-converting enzyme-2 (ACE-2) is one of the most important receptors on the cell membrane of the host cells (HCs) which its interaction with spike protein (SP) with a furin-cleavage site results in the SARS-CoV-2 invasion. Hence, in this review, we presented an overview on the interaction of ACE-2 and furin with SP. As several kinds of CoVs, from various genera, have at their S1/S2 binding site a preserved site, we further surveyed the role of furin cleavage site (FCS) on the life cycle of the CoV. Furthermore, we discussed that the small molecular inhibitors can limit the interaction of ACE-2 and furin with SP and can be used as potential therapeutic platforms to combat the spreading CoV epidemic. Finally, some ongoing challenges and future prospects for the development of potential drugs to promote targeting specific activities of the CoV were reviewed. In conclusion, this review may pave the way for providing useful information about different compounds involved in improving the effectiveness of CoV vaccine or drugs with minimum toxicity against human health.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Hasan
        </lastname>
        <forename>
         Anwarul
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Mechanical and Industrial Engineering, College of Engineering, Qatar University, Doha 2713, Qatar.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Biomedical Research Center, Qatar University, Doha 2713, Qatar.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Paray
        </lastname>
        <forename>
         Bilal Ahamad
        </forename>
        <initials>
         BA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Zoology, College of Science, King Saud University, PO Box 2455, Riyadh 11451, Saudi Arabia.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Hussain
        </lastname>
        <forename>
         Arif
        </forename>
        <initials>
         A
        </initials>
        <affiliationinfo>
         <affiliation>
          School of Life Sciences, Manipal Academy of Higher Education, P.O. Box 345050, Dubai, United Arab Emirates.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Qadir
        </lastname>
        <forename>
         Fikry Ali
        </forename>
        <initials>
         FA
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biology, Salahaddin University-Erbil, Kurdistan Region, Iraq.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Attar
        </lastname>
        <forename>
         Farnoosh
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biology, Faculty of Food Industry and Agriculture, Standard Research Institute (SRI), Karaj, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Aziz
        </lastname>
        <forename>
         Falah Mohammad
        </forename>
        <initials>
         FM
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Biology, Salahaddin University-Erbil, Kurdistan Region, Iraq.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Sharifi
        </lastname>
        <forename>
         Majid
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Derakhshankhah
        </lastname>
        <forename>
         Hossein
        </forename>
        <initials>
         H
        </initials>
        <affiliationinfo>
         <affiliation>
          Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rasti
        </lastname>
        <forename>
         Behnam
        </forename>
        <initials>
         B
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0002-5061-3142
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University (IAU), Lahijan, Guilan, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Mehrabi
        </lastname>
        <forename>
         Masoumeh
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Microbiology, Faculty of Basic Sciences, Lahijan Branch, Islamic Azad University (IAU), Lahijan, Guilan, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Shahpasand
        </lastname>
        <forename>
         Koorosh
        </forename>
        <initials>
         K
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology (RI-SCBT), Tehran, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Saboury
        </lastname>
        <forename>
         Ali Akbar
        </forename>
        <initials>
         AA
        </initials>
        <affiliationinfo>
         <affiliation>
          Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Falahati
        </lastname>
        <forename>
         Mojtaba
        </forename>
        <initials>
         M
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        10
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       J Biomol Struct Dyn
      </medlineta>
      <nlmuniqueid>
       8404176
      </nlmuniqueid>
      <issnlinking>
       0739-1102
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       Coronavirus
      </keyword>
      <keyword majortopicyn="N">
       angiotensin-converting enzyme-2
      </keyword>
      <keyword majortopicyn="N">
       enzyme inhibition
      </keyword>
      <keyword majortopicyn="N">
       furin
      </keyword>
      <keyword majortopicyn="N">
       spike protein
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32274964
      </articleid>
      <articleid idtype="doi">
       10.1080/07391102.2020.1754293
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32274570
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       15
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1435-1803
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          09
         </day>
        </pubdate>
       </journalissue>
       <title>
        Basic research in cardiology
       </title>
       <isoabbreviation>
        Basic Res. Cardiol.
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?
      </articletitle>
      <pagination>
       <medlinepgn>
        31
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1007/s00395-020-0791-5
      </elocationid>
      <abstract>
       <abstracttext>
        From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.
       </abstracttext>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Rizzo
        </lastname>
        <forename>
         Paola
        </forename>
        <initials>
         P
        </initials>
        <identifier source="ORCID">
         0000-0001-7174-9674
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Morphology, Surgery and Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. rzzpla@unife.it.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Maria Cecilia Hospital, GVM Care &amp; Research, Cotignola, Italy. rzzpla@unife.it.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Vieceli Dalla Sega
        </lastname>
        <forename>
         Francesco
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Maria Cecilia Hospital, GVM Care &amp; Research, Cotignola, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Fortini
        </lastname>
        <forename>
         Francesca
        </forename>
        <initials>
         F
        </initials>
        <affiliationinfo>
         <affiliation>
          Maria Cecilia Hospital, GVM Care &amp; Research, Cotignola, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Marracino
        </lastname>
        <forename>
         Luisa
        </forename>
        <initials>
         L
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Morphology, Surgery and Experimental Medicine and Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Rapezzi
        </lastname>
        <forename>
         Claudio
        </forename>
        <initials>
         C
        </initials>
        <affiliationinfo>
         <affiliation>
          Maria Cecilia Hospital, GVM Care &amp; Research, Cotignola, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Center, University Hospital of Cona, Ferrara, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Ferrari
        </lastname>
        <forename>
         Roberto
        </forename>
        <initials>
         R
        </initials>
        <affiliationinfo>
         <affiliation>
          Maria Cecilia Hospital, GVM Care &amp; Research, Cotignola, Italy.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Cardiovascular Center, University Hospital of Cona, Ferrara, Italy.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        09
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       Germany
      </country>
      <medlineta>
       Basic Res Cardiol
      </medlineta>
      <nlmuniqueid>
       0360342
      </nlmuniqueid>
      <issnlinking>
       0300-8428
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D015850">
        Interleukin-6
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D051880">
        Receptors, Notch
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.15.1
       </registrynumber>
       <nameofsubstance ui="D007703">
        Peptidyl-Dipeptidase A
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.17.-
       </registrynumber>
       <nameofsubstance ui="C413524">
        angiotensin converting enzyme 2
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.21.75
       </registrynumber>
       <nameofsubstance ui="D045683">
        Furin
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.24.86
       </registrynumber>
       <nameofsubstance ui="D000072198">
        ADAM17 Protein
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        EC 3.4.24.86
       </registrynumber>
       <nameofsubstance ui="C000606462">
        ADAM17 protein, human
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000072198">
        ADAM17 Protein
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000037">
        antagonists &amp; inhibitors
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000073640">
        Betacoronavirus
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000472">
        pathogenicity
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" type="Geographic" ui="D002681">
        China
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000503">
        physiopathology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018450">
        Disease Progression
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D045683">
        Furin
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006323">
        Heart Arrest
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006331">
        Heart Diseases
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000209">
        etiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000503">
        physiopathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006333">
        Heart Failure
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015850">
        Interleukin-6
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000276">
        immunology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D008171">
        Lung Diseases
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000209">
        etiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000503">
        physiopathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D009205">
        Myocarditis
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000209">
        etiology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D007703">
        Peptidyl-Dipeptidase A
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000172">
        deficiency
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000473">
        pathology
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000503">
        physiopathology
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000821">
        virology
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D051880">
        Receptors, Notch
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000037">
        antagonists &amp; inhibitors
       </qualifiername>
       <qualifiername majortopicyn="N" ui="Q000378">
        metabolism
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D015398">
        Signal Transduction
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000187">
        drug effects
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ADAM17
      </keyword>
      <keyword majortopicyn="Y">
       Angiotensin-converting enzyme 2
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       Cardiovascular disease
      </keyword>
      <keyword majortopicyn="Y">
       Coronavirus disease
      </keyword>
      <keyword majortopicyn="Y">
       Furin
      </keyword>
      <keyword majortopicyn="Y">
       Notch
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        21
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        11
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        16
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32274570
      </articleid>
      <articleid idtype="doi">
       10.1007/s00395-020-0791-5
      </articleid>
      <articleid idtype="pii">
       10.1007/s00395-020-0791-5
      </articleid>
      <articleid idtype="pmc">
       PMC7144545
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Int Arch Allergy Immunol. 2019;179(1):43-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30943513
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Steroid Biochem Mol Biol. 2019 May;189:87-100
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30817989
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Rep. 2015 Jan 13;10(2):239-52
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25558064
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Front Immunol. 2019 May 22;10:1130
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31191522
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2011 Nov;7(11):e1002341
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22072963
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2011 Aug 12;286(32):28312-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21685392
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci Adv. 2017 Apr 05;3(4):e1601556
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28435870
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2005 May;18(5 Pt 1):720-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15882557
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viral Immunol. 2008 Jun;21(2):115-22
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18419253
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Heart J. 2020 Apr 1;41(13):1320-1322
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32236465
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Cardiol. 2020 Mar 5;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32139904
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Heart J. 2014 Aug 21;35(32):2140-5
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24970336
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Apr;92(4):455-459
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31994738
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Ann Rheum Dis. 2015 Jan;74(1):267-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24255545
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 12;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32161940
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Eur Heart J. 2013 Aug;34(32):2504-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         22645188
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Feb 28;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32109013
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Am Heart Assoc. 2014 Oct 27;3(6):e001064
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25349182
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2005 Aug 26;280(34):30113-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15983030
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Neoplasia. 2013 Feb;15(2):218-30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23441135
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Thorac Oncol. 2020 Feb 28;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32114094
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Feb 20;382(8):727-733
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978945
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 6;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32155444
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Virol J. 2019 May 27;16(1):69
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31133031
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2010 Feb;10(2):83-92
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20113977
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Arterioscler Thromb Vasc Biol. 2011 May;31(5):1059-65
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21330605
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Mol Immunol. 2015 Nov;12(6):768-76
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25363527
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Thorac Oncol. 2020 Mar 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32151778
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertens Res. 2006 Nov;29(11):865-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17345786
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Mol Cell Biol. 2015 Nov;35(21):3622-32
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26283728
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Biol Chem. 2007 Jul 20;282(29):20847-53
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17537721
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Expert Opin Ther Targets. 2019 Aug;23(8):695-710
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31304807
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Mol Immunol. 2012 Mar;9(2):155-62
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21983868
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32142651
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Transplantation. 2016 Dec;100(12):2593-2600
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27607530
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Mol Cell Cardiol. 2014 Jan;66:167-76
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24332999
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Basic Res Cardiol. 2013 Sep;108(5):373
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         23989801
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Alzheimers Dis. 2016 Jul 6;53(4):1395-404
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         27392862
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Front Cell Infect Microbiol. 2018 Jul 10;8:241
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30042932
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Jan 23;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31971553
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Intensive Care Med. 2020 Mar 3;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32125452
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nat Rev Immunol. 2007 Jan;7(1):64-75
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         17170755
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Basic Res Cardiol. 2015 May;110(3):29
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25893875
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Cancer Res. 2010 Jul 1;16(13):3378-89
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         20570921
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="PubMed-not-MEDLINE">
     <pmid version="1">
      32269893
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       11
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Print">
        2168-8184
       </issn>
       <journalissue citedmedium="Print">
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          06
         </day>
        </pubdate>
       </journalissue>
       <title>
        Cureus
       </title>
       <isoabbreviation>
        Cureus
       </isoabbreviation>
      </journal>
      <articletitle>
       A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).
      </articletitle>
      <pagination>
       <medlinepgn>
        e7560
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.7759/cureus.7560
      </elocationid>
      <abstract>
       <abstracttext>
        Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.
       </abstracttext>
       <copyrightinformation>
        Copyright © 2020, Kakodkar et al.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Kakodkar
        </lastname>
        <forename>
         Pramath
        </forename>
        <initials>
         P
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Kaka
        </lastname>
        <forename>
         Nagham
        </forename>
        <initials>
         N
        </initials>
        <affiliationinfo>
         <affiliation>
          Medicine, National University of Ireland Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Baig
        </lastname>
        <forename>
         M N
        </forename>
        <initials>
         MN
        </initials>
        <affiliationinfo>
         <affiliation>
          Orthopaedics, University Hospital Galway, Galway, IRL.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016428">
        Journal Article
       </publicationtype>
       <publicationtype ui="D016454">
        Review
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        06
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       Cureus
      </medlineta>
      <nlmuniqueid>
       101596737
      </nlmuniqueid>
      <issnlinking>
       2168-8184
      </issnlinking>
     </medlinejournalinfo>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ace2
      </keyword>
      <keyword majortopicyn="N">
       ards
      </keyword>
      <keyword majortopicyn="N">
       chloroquine
      </keyword>
      <keyword majortopicyn="N">
       covid-19
      </keyword>
      <keyword majortopicyn="N">
       lopinavir and ritonavir
      </keyword>
      <keyword majortopicyn="N">
       mrna-1273 vaccine
      </keyword>
      <keyword majortopicyn="N">
       pandemic
      </keyword>
      <keyword majortopicyn="N">
       remdesivir (gs-5734)
      </keyword>
      <keyword majortopicyn="N">
       sars-cov-2
      </keyword>
      <keyword majortopicyn="N">
       severe acute respiratory infection
      </keyword>
     </keywordlist>
     <coistatement>
      The authors have declared that no competing interests exist.
     </coistatement>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        10
       </day>
       <hour>
        6
       </hour>
       <minute>
        1
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32269893
      </articleid>
      <articleid idtype="doi">
       10.7759/cureus.7560
      </articleid>
      <articleid idtype="pmc">
       PMC7138423
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        Euro Surveill. 2015 Jun 25;20(25):14-8
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26132768
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Drug Discov Ther. 2020;14(1):58-60
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32147628
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32129805
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell Res. 2020 Mar;30(3):269-271
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32020029
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Epidemiol. 2004 Sep 15;160(6):509-16
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15353409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 28;395(10229):1054-1062
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171076
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Med Virol. 2020 Apr;92(4):401-402
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31950516
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nutrients. 2020 Jan 22;12(2):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31978969
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Curr Biol. 2020 Apr 6;30(7):1346-1351.e2
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32197085
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Anesthesiology. 2019 Apr;130(4):581-591
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30676417
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):497-506
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986264
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMJ. 2017 Feb 15;356:i6583
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28202713
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2005 Oct 28;310(5748):676-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16195424
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        BMC Med. 2009 Jun 22;7:30
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         19545404
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2020 Mar;579(7798):270-273
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32015507
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 26;382(13):1199-1207
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31995857
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Radiology. 2020 Feb 26;:200642
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32101510
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Thorax. 2004 Mar;59(3):252-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14985565
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Mar 7;395(10226):809-815
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32151335
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 May;43(5):970-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15007027
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Hypertens. 2015 Jan;28(1):15-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         24842388
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2020 Apr;20(4):425-434
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32105637
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Viruses. 2019 Oct 24;11(11):
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31652964
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 17;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32182409
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2020 Mar;104(3):246-251
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32035997
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Clin Infect Dis. 2020 Mar 09;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32150618
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care Med. 2017 Oct;45(10):1683-1695
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         28787295
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Infect Dis. 2005 Nov;5(11):718-25
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         16253889
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        N Engl J Med. 2020 Mar 18;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32187464
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Sci China Life Sci. 2020 Mar;63(3):457-460
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32009228
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Cell Mol Med. 2015 Aug;19(8):1965-74
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         25766467
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS One. 2018 Nov 5;13(11):e0205535
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30395570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet Respir Med. 2020 Apr;8(4):e21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32171062
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        PLoS Pathog. 2018 Aug 13;14(8):e1007236
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30102747
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        J Hosp Infect. 2016 Mar;92(3):235-50
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         26597631
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):507-513
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32007143
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="Publisher">
     <pmid version="1">
      32266994
     </pmid>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       08
      </day>
     </daterevised>
     <article pubmodel="Print-Electronic">
      <journal>
       <issn issntype="Electronic">
        1096-9071
       </issn>
       <journalissue citedmedium="Internet">
        <pubdate>
         <year>
          2020
         </year>
         <month>
          Apr
         </month>
         <day>
          08
         </day>
        </pubdate>
       </journalissue>
       <title>
        Journal of medical virology
       </title>
       <isoabbreviation>
        J. Med. Virol.
       </isoabbreviation>
      </journal>
      <articletitle>
       Comment on "Organ-protective Effect of Angiotensin-converting Enzyme 2 and its Effect on the Prognosis of COVID-19".
      </articletitle>
      <elocationid eidtype="doi" validyn="Y">
       10.1002/jmv.25848
      </elocationid>
      <abstract>
       <abstracttext>
        We read with great interest the article by Cheng H et al. The authors mentioned that angiotensin-converting enzyme 2 (ACE2) is protective against novel coronavirus disease 2019 (COVID-19). We would like to explain how cytosolic pH increases the COVID-19 infection by affecting the ACE2. In addition, we would like to mention that amiloride, which increases the cytosolic pH, can be used in the COVID-19 treatment. This article is protected by copyright. All rights reserved.
       </abstracttext>
       <copyrightinformation>
        This article is protected by copyright. All rights reserved.
       </copyrightinformation>
      </abstract>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Cure
        </lastname>
        <forename>
         Erkan
        </forename>
        <initials>
         E
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-7807-135X
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Internal Medicine, Ota&amp;Jinemed Hospital, Istanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Cumhur Cure
        </lastname>
        <forename>
         Medine
        </forename>
        <initials>
         M
        </initials>
        <identifier source="ORCID">
         http://orcid.org/0000-0001-9253-6459
        </identifier>
        <affiliationinfo>
         <affiliation>
          Department of Biochemistry, Private Practice, Istanbul, Turkey.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016422">
        Letter
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        08
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       United States
      </country>
      <medlineta>
       J Med Virol
      </medlineta>
      <nlmuniqueid>
       7705876
      </nlmuniqueid>
      <issnlinking>
       0146-6615
      </issnlinking>
     </medlinejournalinfo>
     <citationsubset>
      IM
     </citationsubset>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="N">
       ACE2
      </keyword>
      <keyword majortopicyn="N">
       ACEI
      </keyword>
      <keyword majortopicyn="N">
       ARBs
      </keyword>
      <keyword majortopicyn="N">
       ARDS
      </keyword>
      <keyword majortopicyn="N">
       Amiloride
      </keyword>
      <keyword majortopicyn="N">
       COVID-19
      </keyword>
      <keyword majortopicyn="N">
       SARS-CoV-2
      </keyword>
      <keyword majortopicyn="N">
       acute respiratory distress syndrome
      </keyword>
      <keyword majortopicyn="N">
       angiotensin II receptor blockers
      </keyword>
      <keyword majortopicyn="N">
       angiotensin-converting enzyme 2
      </keyword>
      <keyword majortopicyn="N">
       angiotensin-converting enzyme inhibitors
      </keyword>
      <keyword majortopicyn="N">
       coronavirus disease 2019
      </keyword>
      <keyword majortopicyn="N">
       cytosolic pH
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      aheadofprint
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32266994
      </articleid>
      <articleid idtype="doi">
       10.1002/jmv.25848
      </articleid>
     </articleidlist>
    </pubmeddata>
   </pubmedarticle>
   <pubmedarticle>
    <medlinecitation owner="NLM" status="MEDLINE">
     <pmid version="1">
      32264922
     </pmid>
     <datecompleted>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </datecompleted>
     <daterevised>
      <year>
       2020
      </year>
      <month>
       04
      </month>
      <day>
       13
      </day>
     </daterevised>
     <article pubmodel="Electronic">
      <journal>
       <issn issntype="Electronic">
        1466-609X
       </issn>
       <journalissue citedmedium="Internet">
        <volume>
         24
        </volume>
        <issue>
         1
        </issue>
        <pubdate>
         <year>
          2020
         </year>
         <month>
          04
         </month>
         <day>
          07
         </day>
        </pubdate>
       </journalissue>
       <title>
        Critical care (London, England)
       </title>
       <isoabbreviation>
        Crit Care
       </isoabbreviation>
      </journal>
      <articletitle>
       COVID-19 and the RAAS-a potential role for angiotensin II?
      </articletitle>
      <pagination>
       <medlinepgn>
        136
       </medlinepgn>
      </pagination>
      <elocationid eidtype="doi" validyn="Y">
       10.1186/s13054-020-02862-1
      </elocationid>
      <authorlist completeyn="Y">
       <author validyn="Y">
        <lastname>
         Busse
        </lastname>
        <forename>
         Laurence W
        </forename>
        <initials>
         LW
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Medicine, Emory University, Atlanta, GA, USA. lbusse@emory.edu.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Emory Critical Care Center, Atlanta, GA, USA. lbusse@emory.edu.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Department of Critical Care Medicine, Emory Johns Creek Hospital, 6325 Hospital Parkway, Johns Creek, GA, 30097, USA. lbusse@emory.edu.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Chow
        </lastname>
        <forename>
         Jonathan H
        </forename>
        <initials>
         JH
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Anesthesiology, Division of Critical Care Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         McCurdy
        </lastname>
        <forename>
         Michael T
        </forename>
        <initials>
         MT
        </initials>
        <affiliationinfo>
         <affiliation>
          Departments of Medicine and Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
         </affiliation>
        </affiliationinfo>
       </author>
       <author validyn="Y">
        <lastname>
         Khanna
        </lastname>
        <forename>
         Ashish K
        </forename>
        <initials>
         AK
        </initials>
        <affiliationinfo>
         <affiliation>
          Department of Anesthesiology, Section on Critical Care Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
         </affiliation>
        </affiliationinfo>
        <affiliationinfo>
         <affiliation>
          Outcomes Research Consortium, Cleveland, OH, USA.
         </affiliation>
        </affiliationinfo>
       </author>
      </authorlist>
      <language>
       eng
      </language>
      <publicationtypelist>
       <publicationtype ui="D016421">
        Editorial
       </publicationtype>
      </publicationtypelist>
      <articledate datetype="Electronic">
       <year>
        2020
       </year>
       <month>
        04
       </month>
       <day>
        07
       </day>
      </articledate>
     </article>
     <medlinejournalinfo>
      <country>
       England
      </country>
      <medlineta>
       Crit Care
      </medlineta>
      <nlmuniqueid>
       9801902
      </nlmuniqueid>
      <issnlinking>
       1364-8535
      </issnlinking>
     </medlinejournalinfo>
     <chemicallist>
      <chemical>
       <registrynumber>
        0
       </registrynumber>
       <nameofsubstance ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </nameofsubstance>
      </chemical>
      <chemical>
       <registrynumber>
        11128-99-7
       </registrynumber>
       <nameofsubstance ui="D000804">
        Angiotensin II
       </nameofsubstance>
      </chemical>
     </chemicallist>
     <supplmeshlist>
      <supplmeshname type="Disease" ui="C000657245">
       COVID-19
      </supplmeshname>
      <supplmeshname type="Protocol" ui="C000705127">
       COVID-19 drug treatment
      </supplmeshname>
      <supplmeshname type="Organism" ui="C000656484">
       severe acute respiratory syndrome coronavirus 2
      </supplmeshname>
     </supplmeshlist>
     <citationsubset>
      IM
     </citationsubset>
     <meshheadinglist>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000804">
        Angiotensin II
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000627">
        therapeutic use
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D000806">
        Angiotensin-Converting Enzyme Inhibitors
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="Y" ui="D000073640">
        Betacoronavirus
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D018352">
        Coronavirus Infections
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D006801">
        Humans
       </descriptorname>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D058873">
        Pandemics
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D011024">
        Pneumonia, Viral
       </descriptorname>
       <qualifiername majortopicyn="N" ui="Q000188">
        drug therapy
       </qualifiername>
       <qualifiername majortopicyn="Y" ui="Q000517">
        prevention &amp; control
       </qualifiername>
      </meshheading>
      <meshheading>
       <descriptorname majortopicyn="N" ui="D012084">
        Renin-Angiotensin System
       </descriptorname>
       <qualifiername majortopicyn="Y" ui="Q000502">
        physiology
       </qualifiername>
      </meshheading>
     </meshheadinglist>
     <keywordlist owner="NOTNLM">
      <keyword majortopicyn="Y">
       ACE2
      </keyword>
      <keyword majortopicyn="Y">
       Angiotensin II
      </keyword>
      <keyword majortopicyn="Y">
       COVID-19
      </keyword>
      <keyword majortopicyn="Y">
       Coronavirus
      </keyword>
      <keyword majortopicyn="Y">
       RAAS
      </keyword>
     </keywordlist>
    </medlinecitation>
    <pubmeddata>
     <history>
      <pubmedpubdate pubstatus="received">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        23
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="accepted">
       <year>
        2020
       </year>
       <month>
        03
       </month>
       <day>
        30
       </day>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="entrez">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="pubmed">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        9
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
      <pubmedpubdate pubstatus="medline">
       <year>
        2020
       </year>
       <month>
        4
       </month>
       <day>
        14
       </day>
       <hour>
        6
       </hour>
       <minute>
        0
       </minute>
      </pubmedpubdate>
     </history>
     <publicationstatus>
      epublish
     </publicationstatus>
     <articleidlist>
      <articleid idtype="pubmed">
       32264922
      </articleid>
      <articleid idtype="doi">
       10.1186/s13054-020-02862-1
      </articleid>
      <articleid idtype="pii">
       10.1186/s13054-020-02862-1
      </articleid>
      <articleid idtype="pmc">
       PMC7137402
      </articleid>
     </articleidlist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 13;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32167538
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Mar 11;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32159735
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2011 Aug;58(2):182-9
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         21709209
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Nature. 2003 Nov 27;426(6965):450-4
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         14647384
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Hypertension. 2004 May;43(5):970-6
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15007027
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        JAMA. 2020 Feb 7;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32031570
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Am J Pathol. 2008 May;172(5):1174-83
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         18403595
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Lancet. 2020 Feb 15;395(10223):514-523
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         31986261
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Science. 2020 Mar 13;367(6483):1260-1263
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32075877
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Cell. 2020 Mar 4;:
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         32142651
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Crit Care. 2018 Oct 28;22(1):274
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         30368243
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Circulation. 2005 May 24;111(20):2605-10
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15897343
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
     <referencelist>
      <reference>
       <citation>
        Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21
       </citation>
       <articleidlist>
        <articleid idtype="pubmed">
         15194496
        </articleid>
       </articleidlist>
      </reference>
     </referencelist>
    </pubmeddata>
   </pubmedarticle>
  </pubmedarticleset>
 </body>
</html>